Fidia S.p.A. (BIT:FDA)
0.2101
+0.0011 (0.53%)
Sep 26, 2025, 5:35 PM CET
Fidia Revenue
In the year 2024, Fidia had annual revenue of 17.53M EUR, down -38.98%. Fidia had revenue of 8.11M in the half year ending December 31, 2024, a decrease of -46.72%.
Revenue
17.53M
Revenue Growth
-38.98%
P/S Ratio
0.16
Revenue / Employee
110.28K
Employees
159
Market Cap
2.84M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 17.53M | -11.20M | -38.98% |
Dec 31, 2023 | 28.74M | 4.07M | 16.52% |
Dec 31, 2022 | 24.66M | 485.00K | 2.01% |
Dec 31, 2021 | 24.18M | 2.52M | 11.65% |
Dec 31, 2020 | 21.65M | -24.55M | -53.13% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Leonardo S.p.a. | 18.70B |
Poste Italiane | 13.75B |
Prysmian | 18.98B |
Fincantieri | 8.84B |
Iveco Group | 14.81B |
Interpump Group | 2.06B |
Maire | 6.65B |
Webuild | 12.15B |
Fidia News
- 3 days ago - Dr. Gottlieb on China's biotech strategy: China has become very adept at following U.S. discoveries - CNBC
- 3 days ago - Animal Testing, Human-Based Models, and Artificial Intelligence - Makkah News (صحيفة مكة)
- 4 days ago - Lupin shares edge higher after tentative US FDA approval for HIV drug generic - Business Upturn
- 4 days ago - uniQure: Positive 3-Year AMT-130 Data Leads To Pre-BLA FDA Meeting And Beyond - Seeking Alpha
- 4 days ago - FDA busts Pardi unit using bleaching agent to whiten rasgullas - The Times of India
- 4 days ago - BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL - Nasdaq
- 4 days ago - AstraZeneca (AZN) Receives FDA Priority Review for Enhertu - GuruFocus
- 4 days ago - REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug - Nasdaq